NCT03392389View on ClinicalTrials.gov

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

July 29, 2019

Study Completion Date

July 29, 2019

Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
BIOLOGICAL

mRNA-1653

Escalating dose levels

OTHER

Placebo

Saline

Trial Locations (3)

68134

Meridian Clinical Research, LLC, Omaha

76135

Benchmark Research, Fort Worth

78705

Benchmark Research, Austin

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT03392389 - Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults | Biotech Hunter | Biotech Hunter